http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 05 Nov 2024 07:05:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html <p class="bwalignc"> <i>Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&amp;A and investor relations</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=47abff4a0482ea43314b731b5d828a8d" shape="rect">PureTech Health plc</a> (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseaporttx.com%2F&amp;esheet=54147124&amp;newsitemid=20241105890397&amp;lan=en-US&amp;anchor=Seaport+Therapeutics&amp;index=2&amp;md5=9887a865cdf3162bad6708ab57fe22a2" shape="rect">Seaport Therapeutics</a>, (“Seaport”) a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Names+Lauren+White+as+Chief+Financial+Officer/23926478.html Tue, 05 Nov 2024 07:05:00 -0500 A.01270702 A.06822034 A.13777776 A.26702646 A.26940647 A.38918558 ABBV CCCC IMGN NOVN NVS O.00222301 O.01270742 O.01420039 O.14731390 O.20026344 O.22973220 O.39012842 O.41197774 O.48629524 PRTC PRTC